Background

Antimicrobial resistance is one of the major threats to global health, resulting in an increasing number of people suffering from severe illness or dying due to infections that were once easily curable with antibiotics. *Pseudomonas aeruginosa* represents one of the most concerning pathogens involved in antibiotic resistance where the World Health Organisation has classified this gram-negative bacterium as an ESRAPE organism, and it is also listed in the Priority 1: Critical list. Hence, in this project, we opted for a novel intervention by using aptamers to inhibit the growth of *Pseudomonas aeruginosa*, which can be cost-effective and less laborious. Besides, antimicrobial agents targeting the outer membrane protein (OMP) in Gram-negative bacteria can also be effective at killing or inhibiting bacterial growth as these proteins play an important role in bacteria survival as well as being exposed to the surface, which facilitates direct binding. Aptamer repurposing also reduces the cost and length of new drug development.

Methodology

Unmodified functional DNA aptamers from the Aptagen database were docked with the essential OMP using various docking tools such as HADDOCK 2.4 and HDOCK web server to determine the binding site and binding score of the various aptamers. Aptamers that bind to the active site with a good binding score were synthesized and folded into their 3D structures.

Results and Discussion

Apt31 had the best HADDOCK score, and was found to bind near the active site of the OMP. Interestingly, this aptamer also exhibited significant antibacterial activity from the early stationary growth phase onwards. The addition of the aptamer after the late log phase also exhibited a similar effect. Besides, the antibacterial activity of apt31 was also dose-dependent. Hence, we can deduce that apt31 binds to the active site region and blocks the OMP activity. The major role of this OMP is to fold and insert β-barrel proteins into the outer membrane layer. As apt31 hinders the OMP activity, we postulate that the bacteria cells eventually die due to a lack of OMPs, which are essential for survival and virulence.

Conclusion

We show that the apt31, an aptamer that binds to an antitumor, is capable of binding to OMP in *Pseudomonas aeruginosa*. The aptamer-OMP complex exhibits a significant antibacterial effect in a dose-dependent manner. Future experiments will include the expression of the recombinant OMP and determination of the dissociation constant (Kd) of the aptamer-OMP complex.

Acknowledgement: This work was funded by the School of Science Strategic Funding Scheme 2021, Monash University Malaysia.

P-35

Production of recombinant shark VnAR single domain antibody specific against DENV Type 2 NS1

Boon Hui Kok1, Hui Ting Lim2, Chin Peng Lim2,1, Chui Han Yee Leow2 and Chui Han Heng Leow1

1Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia; 2School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

Correspondence: Chui Han Heng Leow (chuihannegleow@usm.my)

BMC Proceedings 2022, 16(Suppl 7):P-35

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022)

Penang, Malaysia. 11 – 13 October 2022

Background

Dengue virus (DENV) infection is one of the main global health issues leading to high morbidity and death rate. The accuracy of early diagnosis is the key for effective treatment. However, early diagnosis for DENV infection is a great challenge due to the similar onset symptoms of Dengue with other flaviviruses, concurrent infection and cross-reactivity among dengue serotypes and other flaviviruses [1]. Besides, the limitations of conventional monoclonal antibodies (mAbs) also affect the efficiency of diagnostic kits [2]. Alternatively, the variable new antigen receptor (VnAR) found in shark, has recently been identified as a promising diagnostic tool due to its excellent thermostability and capability to target on cryptic epitopes [3]. In this study, a potential clone that recognizing DENV Type 2 NS1 has been isolated and expressed. This recombinant protein was determined to be soluble and potentially developed as a novel reagent for DENV immunodiagnostic platform.

Methodology

A semi-synthetic library of shark VnAR was used for antibody selection. Total of 3 rounds of biopanning was undertaken in respect to isolate potential binders which can specifically recognize DENV Type 2 NS1. The eluted phage from each round of biopanning were subjected to polyclonal and monoclonal phage ELISA. After verified through DNA sequencing, the selected clone was expressed using bacteria expression system, followed by immobilized metal affinity chromatography (IMAC) purification process. The biological functions of recombinant VnAR will then be characterized, including thermostability, specificity and sensitivity towards DENV Type 2 NS1.

Results and Discussion

For monoclonal phage ELISA, G3, Z3 and Z8 clones were identified to possess good affinity towards NS1 and lower cross reaction towards BSA. Thus, Z8 clone was selected to express as a 12 kDa protein with some optimization during protein expression. To verify target protein, the recombinant antibody reacted with anti-His6 antibody was performed using Western Blot. The functional assays of recombinant protein Z8 are currently underway.

Conclusion

Z8 clone isolated from biopanning has been identified as a potent binder. The recombinant anti-NS1 VnAR Z8 antibody was successfully produced in a bacteria expression system. This new binder can be developed as new reagent for DENV immunodiagnostic platform.

Acknowledgement: We would like to thank funding sponsored by Ministry of Higher Education for Fundamental Research Grant Scheme (FRGS) with project code: FRGS/1/2021/SKK06/USM/02/12 and FRGS/1/2022/SK00/USM/02/5 to complete this work.

References


P-37

A fatal case of cerebral malaria complicated with *Gemella bergeri* bacteremia: Role of *Plasmodium* mitochondrial cox3 gene and MALDI-TOF Mass Spectrometry for species identification

Ummu Afeera Zainulabid1,2, Nor Dianah Dian3, Jauhary Effendy Juma4, Petrick Periyasamy5, Najma Kori5, Cheah Saw Kian6, Asrul Abdul Wahab4 and Zulkarnain Md Idris7

1Department of Internal Medicine, School of Medicine, National University of Malaysia; 2Department of Internal Medicine, Kulliyyah of Medicine, International Islamic University Malaysia; 3Department of Parasitology and Medical Entomology, Faculty of Medicine, National University of Malaysia; 4Department of Microbiology and Immunology, Faculty of Medicine, National University of Malaysia; 5Department of Anesthesiology, Faculty of Medicine, National University of Malaysia

Correspondence: Ummu Afeera Zainulabid (ummuafeera@iium.edu.my)

BMC Proceedings 2022, 16(Suppl 7):P-37

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022)

Penang, Malaysia. 11 – 13 October 2022

Background

Dengue virus (DENV) infection is one of the main global health issues leading to high morbidity and death rate. The accuracy of early diagnosis is the key for effective treatment. However, early diagnosis for DENV infection is a great challenge due to the similar onset symptoms of Dengue with other flaviviruses, concurrent infection and cross-reactivity among dengue serotypes and other flaviviruses [1]. Besides, the limitations of conventional monoclonal antibodies (mAbs) also affect the efficiency of diagnostic kits [2]. Alternatively, the variable new antigen receptor (VnAR) found in shark, has recently been identified as a promising diagnostic tool due to its excellent thermostability and capability to target on cryptic epitopes [3]. In this study, a potential clone that recognizing DENV Type 2 NS1 has been isolated and expressed. This recombinant protein was determined to be soluble and potentially developed as a novel reagent for DENV immunodiagnostic platform.
Background
Here, we described a fatal case of a 37-year-old returning traveller from Burkina Faso, West Africa, who presented with an acute fitting episode later diagnosed as cerebral malaria induced by Plasmodium falciparum based on microscopic examination and Plasmodium mitochondrial cytochrome c oxidase III (cox3) gene PCR target. Unfortunately, the patient passed away due to severe malaria with multiorgan failure complicated with Gemella bergeri bacteremia. G. bergeri was identified using MALDI-TOF mass spectrometry.

Methodology
Preliminary evaluation of blood film malaria parasite showed coinfection of P. falciparum and Plasmodium malariae. Further PCR-based detection analysis using the Plasmodium mitochondrial cox3 gene was used to identify the malaria species. The patient’s blood culture revealed gram-positive cocci in clusters, and further identification using MALDI-TOF Mass Spectrometry was done. Informed consent to publish had been obtained.

Results and Discussion
The patient blood sample was positive for P. falciparum based on analysis using a PCR assay targeting the cox3 gene. Further, analysis done at Makmal Kesihatan Awam Kebangsaan confirmed P. falciparum infection. His blood culture revealed gram-positive cocci in clusters, which was later identified as G. bergeri using MALDI-TOF mass spectrometry. Despite the initiation of intravenous artesunate and subsequent parasite count responding and showing parasite clearance, the complication is detrimental. As neurological consequences and death, the patient also had concomitant fatal G. bergeri bacteremia. Initial examination revealed that the patient had poor oral hygiene and a missing tooth which could be the source of Gemella infection, which is common in the oral cavity and a causative organism of septic shock.

Conclusion
This report is the first fatal case of cerebral malaria caused by P. falciparum coinfection with G. bergeri bacteremia. Therefore, it is critical to determine the exact aetiology for appropriate medical management. Plasmodium mitochondrial cox3 gene and MALDI-TOF Mass Spectrometry are useful for species identification, as illustrated in this case.

P-38
Association of MTHFR polymorphism in stroke risk and rehabilitation outcomes
Eric Tzyi Jiaan Chong 1, Kok Yeow Pneh 1,2, Syahshikandar Sybil Shah 2, Yuen Kang Chia 3, Dayang Maryama Awang Daud 4, Elyana Jalil 1, Chek Siang Kelvin Cheng 1 and Ping-Chin Lee 1
1Biotechnology Research Institute, Universiti Malaysia Sabah, Jalan UMS, 88400 Kota Kinabalu, Sabah; 2Faculty of Science and Natural Resources, Universiti Malaysia Sabah, Jalan UMS, 88400 Kota Kinabalu, Sabah; 3Department of Rehabilitation Medicine, Queen Elizabeth Hospital, Jalan Penampang, 88200 Kota Kinabalu, Sabah; 4Neurology Unit, Queen Elizabeth Hospital, Jalan Penampang, 88200 Kota Kinabalu, Sabah;

Correspondence: Eric Tzyi Jiaan Chong (eric_cjty@ums.edu.my);
leepee@ums.edu.my
BMC Proceedings 2022, 16(Suppl 7):P-38

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022)
Penang, Malaysia. 11 – 13 October 2022

Background
There are 12.2 million new stroke cases annually and about 1 million people worldwide are living with stroke aftermath [1]. In Malaysia, stroke is the third leading cause of death. The rs1801133 single nucleotide polymorphism (SNP) in the methylenetetrahydrofolate reductase (MTHFR) gene has been linked to stroke pathogenesis in a recent meta-analysis [2]. To date, there is a lack of study addressing this SNP towards stroke risk and rehabilitation outcomes in the Malaysian population. Hence, this study aims to investigate the association of MTHFR rs1801133 SNP with the risk and rehabilitation outcomes in Malaysian stroke patients.

Methodology
The peripheral blood sample was collected from 251 age-matched individuals (113 stroke patients and 138 healthy controls without a stroke history) with written consent. The genomic DNA was extracted from these blood samples and the rs1801133 SNP was genotyped using a TaqMan® assay approach. The odds ratio and 95% confidence interval were calculated for risk association analysis. The stroke patients were subjected to a special-designed rehabilitation exercise and their pre- and post-exercise assessments including the Barthel index, Fugl-Meyer assessment-upper extremity, and Fugl-Meyer assessment-lower extremity were compared based on their genotypes.

Results and Discussion
This study showed that the presence of a T allele of the rs1801133 SNP had at least a 0.4-fold reduced risk of stroke. This suggests that the T allele of the rs1801133 SNP is protective against a stroke in the Malaysian population. Surprisingly, the finding of this study is in contrast with those reported in the meta-analyses [2,3]. Out of the 31 stroke patients who had completed their special-designed rehabilitation exercises, patients with a homozygous (C/C) genotype showed significant improvement in the post-rehabilitation assessments including the Barthel index, Fugl-Meyer assessment-upper extremity, and Fugl-Meyer assessment-lower extremity.

Conclusion
In conclusion, this study suggests that the MTHFR rs1801133 SNP is a potential biomarker for stroke risk and rehabilitation outcome predictions in Malaysian stroke patients. Data of this study could be useful for stroke management in the country.

Acknowledgement: This study was supported by the Ministry of Higher Education, Malaysia (TRGS00006-SG-2/2014) and Universiti Malaysia Sabah (5880180-SG-2014).

References